ArticleCureus2025
Intradermal Microdroplet Injection of Standard-Diluted Incobotulinumtoxin A for the Treatment of Erythematotelangiectatic Rosacea: A Study From a Dermatology Center in Medellín, Colombia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the Therapeutic Potential of Botulinum Toxin in Treating Post-Acne Sequelae: A Critical Review.Clinical, cosmetic and investigational dermatology · 2026Review
- Objectification of Skin Glow: In Vivo Evaluation of 300 Women in Relation to Age.Journal of cosmetic dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost previous studies of botulinum toxin A (BoNT/A) use for rosacea have reported using hyperdiluted BoNT/A. Different dilutions than the standard practiced dilution for wrinkle treatment result in confusion, especially if there is more than one injector in an office because daily logistics become complicated.
objectiveTo evaluate the safety and efficacy of the use of intradermal injections of incobotulinumtoxin A (INCO) in the standard dilution used for wrinkle treatment (100U vial in 2cc) for the treatment of erythematotelangiectatic rosacea (ETR).
methodsData from 13 patients with ETR treated with INCO were prospectively collected in this single-center, open-label preliminary study. Patients answered the Rosacea-specific Quality-of-Life instrument (RosaQol) questionnaire, and a non-treating blinded dermatologist evaluated the Clinician Erythema Assessment (CEA) score using a five-point grading scale at baseline and 15-day and three-month follow-ups.
resultsA significant decrease occurred in the total RosaQoL score at 15-day and three-month (p<0.001) follow-ups compared to baseline. Baseline CEA score was considered moderate (84.6%) or severe (15.4%). Most patients were assessed as almost clear or mild at the 15-day and three-month follow-ups (99.3% and 88.9%, respectively).
conclusionStandard 2mL dilution INCO, used for aesthetic indications, may be a safe and effective option for treating ETR-related erythema and flushing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.